PT-141 (Bremelanotide) is one of the most scientifically interesting peptides in current research — the first pharmaceutical to treat sexual dysfunction through a central nervous system mechanism rather than vascular effects. Its approval as Vyleesi® (bremelanotide injection) by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women provides an unusually rich clinical data backdrop for a research peptide.
The Melanocortin System: Background
The melanocortin system consists of five receptors (MC1R–MC5R) and their endogenous ligands: α-MSH, β-MSH, γ-MSH, and ACTH. These receptors govern an extraordinary range of biological functions — skin pigmentation (MC1R), anti-inflammatory signaling (MC1R, MC3R), energy homeostasis and metabolism (MC3R, MC4R), exocrine gland function (MC5R), and sexual arousal and motivation (MC3R, MC4R). The breadth of melanocortin biology makes the system one of the most pharmacologically rich targets in peptide research.
PT-141: From Sunless Tanning Research to Sexual Health
The discovery of PT-141’s effects on sexual arousal was serendipitous. Melanotan II (a cyclic α-MSH analogue originally developed as a sunless tanning agent) was being tested at the University of Arizona when researchers unexpectedly observed erections in male research subjects. This observation redirected research toward the melanocortin system’s role in sexual function. PT-141 (a desacetyl form of Melanotan II) was subsequently developed as a more selective compound for sexual dysfunction research.
PT-141 binds both MC3R and MC4R in the central nervous system. MC4R in the paraventricular nucleus of the hypothalamus is believed to be the primary mediator of sexual arousal effects — activation drives dopaminergic signaling in limbic pathways associated with motivation and reward. Unlike PDE5 inhibitors (which act on penile vasculature), PT-141 works “upstream” in the brain’s arousal circuitry, making it effective in cases where vascular mechanisms are intact but desire is impaired.
Clinical Research Data
Phase III clinical trials for bremelanotide (PT-141) in HSDD enrolled 1,267 premenopausal women across two identical randomized controlled trials (RECONNECT studies). Results showed statistically significant improvements in the number of satisfying sexual events (SSE) and decreases in distress related to low desire versus placebo. The trials established bremelanotide as the first centrally-acting approved treatment for female sexual dysfunction.
In male subjects, early Phase II trials demonstrated dose-dependent erections via the central mechanism (hypothalamic dopaminergic activation) — a finding that suggested PT-141 as a potential treatment for psychogenic erectile dysfunction unresponsive to PDE5 inhibitors.
PT-141 in Broader Melanocortin Research
Beyond sexual function research, PT-141 is a valuable tool for studying:
- Hypothalamic circuits: Mapping MC4R-expressing neurons and their projection pathways
- Dopamine-melanocortin interactions: How melanocortin activation interfaces with reward circuitry
- Appetite and metabolism: MC4R’s dual role in sexual arousal AND energy homeostasis (MC4R knockout mice are obese)
- Skin pigmentation: MC1R activation by PT-141 produces mild pigmentation in rodent models
- Anti-inflammatory effects: MC3R-mediated anti-inflammatory signaling is an active research area
Specifications and Research Use
| Parameter | Data |
|---|---|
| IUPAC Name | Cyclo[Nle⁴, D-Phe⁷]-α-MSH(4–10) |
| CAS Number | 189691-06-3 |
| Molecular Weight | 1025.2 g/mol |
| Primary Receptors | MC3R, MC4R (CNS-expressed) |
| Route (research) | Subcutaneous injection (clinical); SC or IP in animal models |
| Half-life (clinical) | ~2.7 hours |
PT-141 (Bremelanotide) is available at Rainbow Peptide with >98% HPLC purity and COA verification.
For Research Use Only (RUO). Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.